TLX:ASXTelix Pharmaceuticals Limited Analysis

Telix Pharmaceuticals (TLX) is trading at AUD 11.29, comfortably above its 20‑day (≈9.9) and 50‑day (≈10.4) simple moving averages but still below the 200‑day average of ≈15.96, indicating short‑term strength within a longer‑term downtrend. The MACD histogram is positive (≈0.24) and the signal line is bearish, producing a bullish MACD reading, while the RSI sits at 59, suggesting the stock is not yet overbought. Volatility is elevated at roughly 79 % over the past 30 days and beta is modestly above market at 1.06, underscoring a high‑risk price profile. On the fundamentals side, revenue surged 49 % year‑over‑year to AUD 804 million and gross margin is healthy at 47.5 %, yet operating margin is thin (≈1.9 %) and the company posted a small net loss (‑0.9 %). Forward earnings per share are projected at AUD 0.0832, flipping the trailing loss of ‑0.03 EPS, but the forward P/E of ~136 dwarfs the industry average of ~26, flagging significant valuation pressure. The balance sheet shows AUD 142 million in cash against AUD 467 million of debt, yielding a debt‑to‑equity ratio of 112 % and a max drawdown of ‑70 %, which amplifies financial risk.
Recent material news includes a filing for marketing authorization (Feb 18 2026) and the release of FY 2025 results (Feb 20 2026), both of which have drawn analyst attention and underpin a strong‑buy consensus from 12 analysts. The lead rADC candidate TLX591 is in Phase 3 for advanced prostate cancer, and the company reported meeting key objectives in that study, adding near‑term catalyst potential. Consensus target prices average AUD 22.9 (median 20.8), implying upside of over 100 % from current levels, but this upside is tempered by the heavy debt load and high valuation multiples. Given the blend of strong revenue growth, pipeline momentum, and bullish technical signals, the short‑term outlook is cautiously optimistic, while the longer‑term picture hinges on successful regulatory approvals and debt reduction.